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Abstract: Purpose: To correlate inflammatory and proangiogenic key cytokines from undiluted vitreous of treatment-
naïve central retinal vein occlusion (CRVO) patients with SD-OCT parameters. 
Methods: Thirty-five patients (age 71.1 years, 24 phakic, 30 nonischemic) underwent intravitreal combination therapy, 
including a single-site 23-gauge core vitrectomy. Twenty-eight samples from patients with idiopathic, non-uveitis 
floaterectomy served as controls. Interleukin 6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and vascular 
endothelial growth factor (VEGF-A) levels were correlated with the visual acuity (logMar), category of CRVO (ischemic 
or nonischemic) and morphologic parameters, such as central macular thickness-CMT, thickness of neurosensory retina-
TNeuro, extent of serous retinal detachment-SRT and disintegrity of the IS/OS and others. 
Results: The mean IL-6 was 64.7pg/ml (SD ± 115.8), MCP-1 1015.7 ( ± 970.1), and VEGF-A 278.4 ( ± 512.8), which was 
significantly higher than the control IL-6 6.2 ± 3.4pg/ml (P=0.06), MCP-1 253.2 ± 73.5 (P<0.0000001) and VEGF-A 7.0 
± 4.9 (P<0.0006). All cytokines correlated highly with one another (correlation coefficient r=0.82 for IL-6 and MCP-1; 
r=0.68 for Il-6 and VEGF-A; r=0.64 for MCP-1 and VEGF-A). IL-6 correlated significantly with CMT, TRT, SRT, 
dIS/OS, and dELM. MCP-1 correlated significantly with SRT, dIS/OS, and dELM. VEGF-A correlated not with changes 
in SD-OCT, while it had a trend to be higher in the ischemic versus the nonischemic CRVO group (P=0.09). 
Conclusions: The inflammatory cytokines were more often correlated with morphologic changes assessed by SD-OCT, 
whereas VEGF-A did not correlate with CRVO-associated changes in SD-OCT. VEGF inhibition alone may not be 
sufficient in decreasing the inflammatory response in CRVO therapy. 
Keywords: Vitreous samples, CRVO, VEGF, MCP-1, IL-6, CBA, SD-OCT. 
INTRODUCTION 
  Today, we can assess CRVO patients not only for 
changes in central macular thickness (CMT), but we can also 
conduct a detailed analysis of the neurosensory retina layers. 
Prognosis on visual acuity can be based upon the integrity of 
the IS/OS (photoreceptor inner and outer segments) and the 
external limiting membrane (ELM), which are important 
landmarks for good visual acuity rehabilitation. The 
development of subfoveal serous detachment seems thereby 
to be a potential negative clinical indicator [1-4]. In terms of  
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reducing the frequent intravitreal reinjections, careful SD-
OCT analysis allows for flexible anti-VEGF treatment, 
which has demonstrated significant functional and anatomic 
changes [5]. 
  Macular edema secondary to central retinal vein 
occlusion (CRVO) occurs after multifactorial 
pathophysiologic changes, which affects intraocular cytokine 
levels [6-8]. Cytokines mediate between endothelial cells 
(EC) and inflammatory cells, which themselves interact with 
cytokine expression [9, 10]. The prolonged contact of ECs to 
proinflammatory cytokines might promote more thrombosis 
on top of the initial venous occlusion. Upregulated vascular 
endothelial growth factor (VEGF) is thereby a known 
chemoattractant cytokine for macrophages and leukocytes 12    The Open Ophthalmology Journal, 2013, Volume 7  Koss et al. 
and thus plays an important role in the pathophysiologic 
dysbalance of CRVO [11]. 
 Funk  et al. recently demonstrated that anti-VEGF 
monotherapy has impact on the expression of VEGF and 
inflammatory markers, including interleukin 6 (IL-6) and 
monocyte chemoattractant protein 1 (MCP-1) [6]. IL-6 
thereby is a major promoter of acute-phase proteins. 
Secondly it mediates by VEGF the change from acute to 
chronic inflammation, as it thus combines the inflammatory 
process with angiogenesis [12]. It could be demonstrated that 
the severity of macular edema (ME) is correlated with 
cytokine dysbalance [13]. 
  Our group has previously described the rationale and the 
clinical outcome of a combination therapy including a core 
vitrectomy with the application of anti-VEGF agents and 
steroids and we have described the differences of intravitreal 
cytokines in different RVO categories [14,15]. Thereby we 
were able to acquire undiluted vitreous from CRVO patients 
before the drug injection and correlate the load of cytokines 
with detailed intraretinal layer changes assessed with SD-
OCT. 
METHODS 
  This study was conducted after local institutional review 
board (IRB) approval. Following the sixth revision of the 
Declaration of Helsinki each participating patient consented 
to the study. 
  Patients were included with a CRVO associated 
significant macular edema (CSME) involving the fovea, but 
a macular thickness of not more than 1000 μm, which led to 
a visual acuity of not worse than 2.0 LogMAR. Not included 
were patients with CRVO associated complications, like iris 
rubeosis or neovascularization. Excluded were additionally 
patients with a history of previous intravitreal drug injections 
or surgery. 
  Early Treatment Diabetic Retinopathy Study (ETDRS) 
best-corrected visual acuity (BCVA) was assessed at 5 m 
with stopping at three out of five optotypes and presented as 
the logarithm of the minimum angle of resolution 
(LogMAR). 
  A SD-OCT (SD-OCT; 3D OCT-2000; Topcon, Tokyo, 
Japan) scan depth of 2.3 mm with a horizontal resolution of 
20μm, and a longitudinal resolution of 5–6 μm was acquired 
at an A-scan speed of 27.000 A scans/second. 
  Consecutive sections and vertical and horizontal scans 
within the macular region were obtained by a well-trained 
OCT-certified technician (certification by the reading center, 
Vienna, Austria). Using OCT images, a standardized reading 
protocol was performed on OCT scans with a quality score 
over 16 dB, including six measurements (Fig. 1): 
1.  Central macular thickness (CMT) was calculated as 
the distance of the inner limiting membrane (ILM) to 
the basal membrane (BM) of the retinal pigment 
epithelium (RPE) including all compartments in 
between. 
2.  Total retinal thickness (TRT) was defined as the 
biggest distance of the ILM to the BM of the RPE 
within the 3D scan field (127 A-scans), including 
3.  The Thickness of the neurosensory retina (TNeuro) 
and 
4.  The Subfoveal serous retinal thickness (SRT) and 
5.  The disintegrity of the inner and outer photoreceptor 
segments (dIS/OS) 
6.  The disintegrity of the external limiting membrane 
(dELM), both at the foveal region. 
  These measurements were reviewed with a caliper that 
was built into the software of the OCT machine by two 
retina specialists (M.P./F.K.) who were blinded to the visual 
acuity results and the results of the cytokine evaluation. 
Intergrader reliability () was assessed with a  value of 0.88 
to 0.95. Additionally, the A-scans were evaluated for the 
occurrence of intraretinal cysts or hyperreflective spots. To 
exclude false positive occurrence of disrupted/ disintegrated 
IS/OS or ELM sections due to overlying cystic edema or 
intraretinal bleeding a-scans were scrolled through the 
macular region. Ischemic retinopathy was declared with >ten 
disc areas of nonperfusion with fluorescein angiography 
using the OIS WinStation (11K™, CCS Pawlowski GmbH, 
Jena, Germany). In case of early, fresh CRVO with extensive 
hemorrhages blocking retinal parts, FA was delayed until 
bleeding cleared up. 
  The surgical technique that yielded the sample collection 
was described earlier [16]. Briefly, 0.6 to 0.8ml of undiluted 
vitreous fluid from the mid- to posterior vitreous cavity were 
extracted by an assistant under the guidance of the surgeon, 
who controlled the vitrector with a headset and a magnifying 
28-diopter lens. 
  Samples from idiopathic, non-uveitic floaterectomy 
served as controls. All samples were saved prior to drug 
application and frozen at –80°C. 
  The cytometric bead array system with flex sets (BD™, 
Heidelberg, Germany) was used to determine IL-6, MCP-1 
and VEGF-A according to the manufacturer´s instruction 
manual including the measurement on a FACSArray™ 
Bioanalyzer (BD™, Heidelberg, Germany) with FCAP array 
software (BD™, Heidelberg, Germany). The data were 
saved in EXCEL
 (Microsoft Office 2010, Redmond, USA) 
and statistically analyzed with Bias
 software (Version 8.3.8, 
Epsilon, Darmstadt, Germany). The data had a non-
parametrical distribution, which was checked with the 
David's test (error level of 5%), thus the Wilcoxon-Mann-
Whitney test could be applied with a P value of <0.05. 
  Spearman rank correlation coefficient was used to 
examine the relationship between the influences of the 
cytokines on other parameters, like or changes in SD-OCT. 
RESULTS 
Patients 
  The CRVO group (14 men and 21 women) was aged 71.1 
± 11.7 years (mean ± standard deviation - SD), and the 
control group (12 men and 16 women) was aged 66.2 ± 7.9 
years (P=0.89 and 0.17, respectively, Table 1). The visual 
acuity was 1.28 ± 0.59 LogMAR in the CRVO group and 
0.51 ± 0.22 in the control group (P<0.001). Twenty-four out 
of 35 in the CRVO group and 8 out 28 in the control group Correlation from Undiluted Vitreous Cytokines  The Open Ophthalmology Journal, 2017, Volume 7    13 
were phakic (P<0.005). Among the 35 CRVO patients, 30 
were nonischemic. The duration of the CRVO was 7.4 ± 3.5 
months for all CRVO patients and all were treatment naïve 
before study start. The patients were distributed in a 
subgroup of fresh CRVO with a duration of 5.1 ± 2.0 months 
(n=22) and a subgroup of old CRVO (n=13) with a duration 
of 11.2 ± 1.6 months after onset of the disease (P<0.001). 
Table  1.  Epidemiologics: Values in Mean ( ± Standard 
Deviation), Blood Pressure in mmHg, Duration of 
CRVO in Months, Ischemic Signs, Including Cotton 
Wools, Massive Intraretinal Haemorrhage, Enlarged 
Foveolar Avascular Zone, Capillary Drop-Outs, 
Area of Non-Perfusion > 5 Disc Areas, Differences 
are Calculated with Wilcoxon-Mann-Whitney Test 
 
 CRVO  Control  P  Value 
N  35  28   
Male/Female  14/21 12/  16  0.89 
Age in years  71.1 ± 11.7  66.2 ± 7.9  0.17 
Blood Pressure      
Systolic  141 ± 18  121 ± 10  < 0.01 
Diastolic  83 ± 14  75 ± 8  0.09 
Hypertension  24  5  0.003 
Drug therapy  22 3  0.004 
VA in logMar  1.28 ± 0.59  0.51 ± 0.22  < 0.001 
Pseudophakic/Phakic  11/24 20/8  < 0.005 
Duration of CRVO   7.4 ± 3.5     
CRVO 
Type  Fresh  Older   
N  22 13   
Ischemic/Nonischemic  3 / 19  2 / 11  0.96 
Duration of CRVO   5.1 ± 2.0  11.2 ± 1.6  < 0.001 
 
SD-OCT 
  The mean absolute values ± SD with the 95% confidence 
interval (CI) of the SD-OCT measurements are depicted in 
μm in Table 2. For all CRVO patients, the mean CMT was 
549.3 ± 243.7 (CI 465.6-633μm), the TRT was 742.9 ± 
256.3 (CI 654.8–830.9), the TNeuro was 555.5 ± 123.9 (CI 
512.9–598.1), the SRT was 186.3 ± 149.4 (CI 134.9-237.6), 
the dIS/OS was 3252.1 ± 1321.3 (CI 2798.2–3705.9), and 
the dELM was 3649.8 ± 1214.7 (CI 3232.5–4067.1). In 34 
out of 35 patients (97%), intraretinal cysts were noted, while 
in 8 out of 35 patients (23%), hyperreflective spots occurred. 
For the nonischemic and ischemic patients, higher values 
were observed for all SD-OCT parameters in the ischemic 
group, aside from subretinal thickness (SRT). This 
difference had a statistical trend for CMT (p=0.08), TNeuro 
(p=0.07), and the occurrence of intraretinal cysts (p=0.06). 
But regarding the SD-OCT parameters there was no 
statistical significant difference in the subgroups (old versus 
fresh and phakic versus pseudophakic). 
Correlation of SD-OCT 
  CMT correlated significantly (please see Table 3) with 
TRT (r=0.83), with TNeuro (r=0.37), with SRT (r=0.42), 
with dIS/OS (r=0.49), with dELM (r=0.43), and inversely 
with intraretinal cysts (r= -0.52). TRT correlated 
significantly with TNeuro (r=0.55), with SRT (r=0.49), with 
dIS/OS (r=0.45), and with dELM (r=0.44). TNeuro and SRT 
correlated significantly with dIS/OS (r=0.41 and 0.51) and 
with dELM (r=0.45 and 0.54). DIS/OS and dELM correlated 
significantly with another (r=0.91). In total correlated CMT 
with six, dIS/OS and ELM with five, TRT with four, and 
TNeuro and SRT with two SD-OCT parameters. 
Vitreal Cytokine Levels 
  The mean IL-6 vitreal, MCP-1 and VEGF-A levels can 
be found in Table 2 and Fig. (2). 
  The IL-6 level was 66.8 ± 124.6 (CI 20.3–113.4) in the 
nonischemic CRVO group, the MCP-1 level was 1043.3 ± 
 
Fig. (1). Cystoid macular edema secondary to a fresh CRVO assessed by SD-OCT with marked total retinal thickness (TRT), thickness 
neurosensory (TNeuro), and subretinal thickness marked as subretinal fluid (SRT) measured in μm 14    The Open Ophthalmology Journal, 2013, Volume 7  Koss et al. 
1037.7 (655.8-1431), and the VEGF-A level was 277.7 ± 
551.9 (71.6–484). In the ischemic group, the level of IL-6 
was 51.7 ± 33 (CI 10.6–92.8, P=0.35), and the level of MCP-
1 was 850.6 ± 390.4 (CI 365.8–1335, P=0.57). The VEGF-A 
level was higher in the ischemic group than in the 
nonischemic group, at 282.5 ± 165.9 (CI 76.4–488.6). The 
differences between the lens status was not significant. IL-6 
was 71.7 ± 140.8 (CI -22.9–166.3) in the pseudophakic 
group and 61.5 ± 105.6 (CI 16.9–106, P=0.92) in the phakic 
group. The levels of MCP-1 were 1315.1 ± 1477.7 (CI 
322.1–2308) and 878.6 ± 615.9 (CI 618–1139, P=0.43), 
while the level of VEGF-A was 249.5 ± 448.9 (CI -52.1–
551.1) and 291.6 ± 548.2 (CI 60.1–523.1, P=0.34), 
respectively. 
Correlation Between Cytokines 
  In the CRVO group, all cytokines were positively 
correlated with one other. IL-6 was positively correlated 
(Table 3) with both MCP-1 (r=0.82; P<0.0001) and VEGF-A 
(r=0.75; P<0.0001), MCP-1 was correlated with VEGF-A 
(r=0.62; P<0.0001). This was confirmed in the nonischemic 
CRVO subgroup analysis, where the IL-6 level was 
correlated with MCP-1 (r=0.83; P<0.0001) and VEGF-A 
(r=0.76; P<0.0001), and MCP-1 levels were correlated with 
VEGF-A (r=0.63; P<0.0002). In the ischemic subgroup, 
however, there was no significant correlation among the 
cytokines. Analysis of the pseudophakic versus the phakic 
subgroup yielded positive correlation coefficients for all   
three cytokines. In the pseudophakic group, the following 
correlations were observed: IL-6 and MCP-1: r=0.71, 
P<0.0001; IL-6 and VEGF-A: r=0.66, P<0.0004; MCP-1 and 
VEGF-A: r=0.51, P<0.01. In the phakic group, the following 
correlations were observed: IL-6 and MCP-1: r=0.98, 
P<0.0001; IL-6 and VEGF-A: r=0.99, P<0.0001; MCP-1 and 
VEGF-A: r=0.99, P<0.0001. 
Correlation of Cytokines with SD-OCT 
  IL-6 correlated more often with SD-OCT parameters than 
did MCP-1 (five times versus three times). IL-6 correlated 
significantly with CMT (r=0.53; P<0.001), TRT (r=0.49; 
P<0.003), SRT (r=0.41; P<0.02), dIS/OS (r=0.56; P<0.001), 
and dELM (r=0.58; P<0.003). MCP-1 correlated 
significantly with SRT (P<0.04); dIS/OS (r=0.38; P<0.02), 
and dELM (r=0.36; p<0.03). VEGF-A did not correlate with 
CRVO-associated changes in SD-OCT. 
Visual Acuity 
  Visual acuity was analyzed with LogMAR values and 
correlated to objective SD-OCT parameters and the vitreal 
Table 2.  Characteristics of the SD-OCT Measurements (Please See Fig. 1) 
 
CRVO 
SD-OCT 
All 
N=35 
Nonischemic 
N=30 
Ischemic 
N=5 
P value  Pseudophakic 
N=11 
Phakic 
N=24 
P Value 
CMT 
549.3 ± 243.7 
(465.6-633) 
521.8 ± 238.9 
(432.5-611) 
714.8 ± 225.8 
(434.5-995.1)  
0.08 
475.9 ± 221.4 
(327.2-624.7) 
583 ± 250.5 
(477.2-688.8) 
0.17 
TRT 
742.9 ± 256.3 
(654.8-830.9) 
717.6 ± 245.7 
(625.8-809.4) 
894.6 ± 295.3 
(527.9-1261.3) 
0.15 
669.7 ± 292 
(473.5-865.9) 
776.4 ± 237.3 
(676.2-876.6) 
0.15 
TNeuro 
555.5 ± 123.9 
(512.9-598.1) 
538.1 ± 119.9 
(493.4-582.9) 
659.8 ± 101.9 
(533.2-786.4) 
0.07 
562.9 ± 154.4 
(459.2-666.6) 
552.1 ± 110.8 
(505.3-598.9) 
0.84 
SRT 
186.3 ± 149.4 
(134.9-237.6) 
192.9 ± 146.2 
(138.3-247.5) 
146.6 ± 180.1 
(-77.1-370.2) 
0.42 
162.8 ± 134.9 
(72.2-253.5) 
197.1 ± 157.1 
(130.7-263.4) 
0.47 
dIS/OS 
3252.1 ± 1321.3 
(2798-3706) 
3143.8 ± 1333 
2646-3642) 
3902 ± 1158.1 
(2464-5340) 
0.24 
3210.3 ± 1716.9 
(2057-4364) 
3271.3 ± 1139.3 
(2790-3752) 
 
0.93 
dELM 
3649.8 ± 1214.7 
(3233-4067) 
3525.3 ± 1234.9 
(3064-3986) 
4396.8 ± 820.2 
(3378-5415) 
0.24 
3389.5 ± 1560 
(2341-4438) 
3769.1 ± 1037.1 
(3331-4207) 
0.49 
Cysts  34  30  4  0.06  11  23  0.16 
HR-Spots  8 8  0  0.37  3  5  0.79 
CRVO Cytokines 
  All  Control  P value  Nonischemic  Ischemic  P value  Pseudophakic  Phakic  P value 
IL-6 
64.7 ± 115.8 
(24.9-104.4) 
6.2 ± 3.4 
(4.9-7.5)  
0.06 
66.8 ± 124.6 
(20.3-113.4) 
51.7 ± 33 
(10.6-92.8) 
0.35 
71.7 ± 140.8 
(-22.9-166.3) 
61.5 ± 105.6 
(16.9-106) 
0.92 
MCP-1 
1015.8 ± 970.1 
(682.5-1349) 
253 ± 74 
(225-282) 
0.001 
1043.3 ± 1037.7 
(655.8-1431) 
850.6 ± 390.4 
(365.8-1335) 
0.57 
1315.1 ± 1477.7 
(322.3-2308) 
878.6 ± 615.9 
(618-1139) 
0.43 
VEGF-A 
278.4 ± 512.8 
(102.2-454.5) 
7 ± 4.9 
(5.1-8.9) 
0.001 
277.7 ± 551.9 
(71.6-484) 
282.5 ± 165.9 
(76.4-488.6) 
0.09 
249.5 ± 448.9 
(-52.1-551.1) 
291.6 ± 548.2 
(60.1-523.1) 
0.34 
All measurements are depicted as mean values ± standard deviation (SD) in μm. The 95% confidence interval values are depicted in brackets; CMT=central macular thickness, 
TRT=total retinal thickness; TNeuro=thickness neurosensorium; SRT=subretinal thickness; dIS/OS= discontinued inner and outer photoreceptor segment band in the fovea; 
dELM=discontinued external limiting membrane band; Cysts=intraretinal cysts; HR spots= hyperreflective spots. The absolute mean values of the vitreous cytokines ± standard 
deviation (SD) are in pg/ml with the 95% confidence interval values in brackets. Correlation from Undiluted Vitreous Cytokines  The Open Ophthalmology Journal, 2017, Volume 7    15 
cytokine values (Table 3). There was no significant 
correlation between any of the parameters and visual acuity. 
DISCUSSION 
  We could demonstrate, that primarily the inflammatory 
cytokines were more often correlated with morphologic 
changes assessed by SD-OCT, whereas VEGF-A did not 
correlate with CRVO-associated changes in SD-OCT. 
  Recent studies with SD-OCT have shown that macular 
edema secondary to retinal vein occlusion is often 
characterized by numerous cystoid spaces and marked retinal 
swelling, especially in the outer retinal layers. We are not 
aware, that there is a correlation of SD-OCT parameters with 
intraocular cytokine levels published up to date. In our study, 
IL-6 correlated more often with SD-OCT parameters than 
MCP-1, whereas VEGF-A did not correlate with CRVO-
associated changes in SD-OCT (Table 3). CRVO macular 
edema is often accompanied by serous retinal detachment, 
which might occur as pointed or dome-shaped and might be 
associated with a poorer visual acuity prognosis [1]. The 
most suitable predictor of visual acuity, however, seems to 
be the integrity of the photoreceptor layer and the integrity of 
the external limiting membrane [3, 4]. Subretinal thickness, 
dIS/OS, and dELM were significantly correlated with the 
inflammatory marker IL-6 and not with VEGF-A. The visual 
acuity at the time of combination therapy was not correlated 
with objective SD-OCT parameters or the cytokines. Cystoid 
spaces themselves are often accompanied by hyperreflective 
spots, which might indicate chronicity [17]. Cystoid spaces 
and hyperreflective spots were correlated with central 
macular thickness and IL-6, which might underline 
chronicity. MCP-1, however, was not correlated with cystoid 
space or with hyperreflective spots. Generally, the role of 
MCP-1 in the pathophysiology of RVO is until today not 
well perceived. It has strong eosinophilic chemotactic 
properties and is crucial in monocyte recruitment at the 
endocytes, which supports the role of eosinophils in tissue 
remodeling [18]. 
  It is noteworthy that in our study all cytokines are 
positively correlated with each other (Table 3), which was 
highly statistically significant. Because of one limitation of 
our study, the relatively small number of ischemic CRVO 
patients (n=5), we can only speculate about the implication 
of the results in terms of the comparison between ischemic 
versus nonischemic patients. While Noma et al. were able to 
demonstrate elevated IL-6 and VEGF levels in 18 ischemic 
CRVOs (versus 9 nonischemic CRVO) [7], we could not 
confirm this observation (Fig. 3). There was a trend towards 
elevated VEGF-A levels in the ischemic group (p=0.09), but 
the correlation among the cytokines was insignificant, while 
there was a positive correlation between the cytokines in the 
Table 3.  Spearman Rang Correlation Matrix 
 
  VA  CMT  TRT  TNeuro  SRT  dIS/OS dELM  Cysts  Ischemic  IL-6  MCP-1 VEGF-A 
VA    0.15 
(0.39) 
0.14 
(0.42) 
-0.04 
(0.80) 
0.27 
(0.11) 
0.26 
(0.13) 
0.16 
(0.35) 
-0.04 
(0.81) 
-0.27 
(0.12) 
0.25 
(0.15) 
0.26 
(0.12) 
0.15 
(0.8) 
CMT     0.83 
(0.001) 
0.37 
(0.03) 
0.42 
(0.01) 
0.49 
(0.003) 
0.43 
(0.01) 
-0.52 
(0.002) 
-0.30 
(0.08) 
0.53 
(0.001) 
0.21 
(0.23) 
0.33 
(0.05) 
TRT        0.55 
(0.001) 
0.49 
(0.003) 
0.45 
(0.01) 
0.44 
(0.01) 
-0.22 
(0.21) 
-0.25 
(0.14) 
0.49 
(0.003) 
0.29 
(0.10) 
0.33 
(0.06) 
TNeuro      0.18 
(0.30) 
0.41 
(0.02) 
0.45 
(0.01) 
-0.02 
(0.90) 
-0.32 
(0.07) 
0.18 
(0.30) 
0.10 
(0.57) 
0.18 
(0.30) 
SRT            0.51 
(0.002) 
0.54 
(0.001) 
-0.13 
(0.47) 
0.15 
(0.39) 
0.41 
(0.02) 
0.35 
(0.04) 
0.05 
(0.79) 
dIS/OS        0.91 
(0.001) 
-0.28 
(0.11) 
-0.21 
(0.21) 
0.56 
(0.001) 
0.30 
(0.08) 
0.20 
(0.24) 
dELM                -0.28 
(0.11) 
-0.21 
(0.21) 
0.58 
(0.003) 
0.38 
(0.02) 
0.35 
(0.04) 
Cysts           0.40 
(0.02) 
-0.12 
(0.50) 
0.19 
(0.28) 
-0.02 
(0.90) 
Ischemic                    -0.17 
(0.33) 
-0.11 
(0.55) 
-0.28 
(0.10) 
IL-6          
 
   0.82 
(0.001) 
0.68 
(0.001) 
MCP-1                        0.64 
(0.001) 
VEGF-A            
 
  
 
 
Subjective (logMar-VA) and objective (SD-OCT) values are correlated with each other and with the values for vitreal cytokines (IL-6, MCP-1, and VEGF-A). The results are 
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nonischemic group. Based on routine clinical practice [10, 
19] and previous preclinical publications [20, 21], it is likely 
that in CRVO with retinal ischemia, VEGF and IL-6 are both 
higher than in nonischemic CRVO. Cataract extraction after 
ischemic CRVO may imply a clinical risk of developing 
rubeosis iridis, but generally the implication of lens status 
(phakic or pseudophakic) is not well understood. We did not 
observe a significant difference between the two subgroups. 
The limitations of our study are a small sample size, which 
may have to oversee especially in the ischemic CRVO group 
significant differences. 
  In conclusion, we demonstrated significantly higher 
values of inflammatory and proangiogenic cytokines in eyes 
with “fresh”, treatment-naïve CRVO eyes as compared with 
control eyes. Although there was no correlation between 
morphologic SD-OCT parameters and visual acuity seven 
months after CRVO onset, inflammatory cytokines, IL-6 and 
MCP-1 were more often correlated with predictive 
morphologic changes (SRT, IS/OS, ELM), which are 
clinically important in visual acuity prognosis, than VEGF-
A. VEGF-A had a tendency to be higher in the ischemic than 
in the nonischemic CRVO group. 
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